A Two-Part, Phase II, Multi-center Study of the ERK Inhibitor Ulixertinib (BVD-523) for Patients with Advanced Malignancies Harboring MEK or Atypical BRAF Alterations
Clinical Trial Grant
Administered By
Duke Cancer Institute
Awarded By
BioMed Valley Discoveries
Start Date
December 15, 2020
End Date
November 26, 2025
Administered By
Duke Cancer Institute
Awarded By
BioMed Valley Discoveries
Start Date
December 15, 2020
End Date
November 26, 2025